keyword
MENU ▼
Read by QxMD icon Read
search

cetuximab AND radiotherapy

keyword
https://www.readbyqxmd.com/read/28056412/toxicity-of-concurrent-stereotactic-radiotherapy-and-targeted-therapy-or-immunotherapy-a-systematic-review
#1
REVIEW
Stephanie G C Kroeze, Corinna Fritz, Morten Hoyer, Simon S Lo, Umberto Ricardi, Arjun Sahgal, Rolf Stahel, Roger Stupp, Matthias Guckenberger
BACKGROUND AND PURPOSE: Both stereotactic radiotherapy (SRT) and immune- or targeted therapy play an increasingly important role in personalized treatment of metastatic disease. Concurrent application of both therapies is rapidly expanding in daily clinical practice. In this systematic review we summarize severe toxicity observed after concurrent treatment. MATERIAL AND METHODS: PubMed and EMBASE databases were searched for English literature published up to April 2016 using keywords "radiosurgery", "local ablative therapy", "gamma knife" and "stereotactic", combined with "bevacizumab", "cetuximab", "crizotinib", "erlotinib", "gefitinib", "ipilimumab", "lapatinib", "sorafenib", "sunitinib", "trastuzumab", "vemurafenib", "PLX4032", "panitumumab", "nivolumab", "pembrolizumab", "alectinib", "ceritinib", "dabrafenib", "trametinib", "BRAF", "TKI", "MEK", "PD1", "EGFR", "CTLA-4" or "ALK"...
December 19, 2016: Cancer Treatment Reviews
https://www.readbyqxmd.com/read/28033526/induction-chemotherapy%C3%A2-followed-by-radiotherapy-for-larynx-preservation-in-advanced-laryngeal-and-hypopharyngeal-cancer-outcome-prediction-after-one-cycle-induction-chemotherapy-by-a-score-based-on-clinical-evaluation-computed-tomography-based-volumetry%C3%A2-and
#2
Gunnar Wichmann, Anne Krüger, Andreas Boehm, Marlen Kolb, Mathias Hofer, Milos Fischer, Stefan Müller, Sandra Purz, Patrick Stumpp, Osama Sabri, Andreas Dietz, Regine Kluge
BACKGROUND: Long-term laryngectomy-free (LFS), tumour-specific (TSS) and overall survival (OS) is achieved by non-surgical larynx preservation (LP) only in a proportion of patients with locally advanced laryngeal or hypopharyngeal cancer. A score facilitating decision-making after 1 cycle induction chemotherapy (IC-1) may improve LFS and TSS. METHODS: Early response to IC-1 with TPF ± cetuximab was assessed in 52 patients using endoscopic tumour staging for selecting total laryngectomy for non-responders with endoscopic tumour surface shrinkage <30% versus induction chemotherapy plus radiotherapy (IC + RT) for responders...
December 26, 2016: European Journal of Cancer
https://www.readbyqxmd.com/read/28032952/clinical-outcome-of-salvage-neck-dissections-in-head-and-neck-cancer-in-relation-to-initial-treatment-extent-of-surgery-and-patient-factors
#3
Karlijn van den Bovenkamp, Maartje G Noordhuis, Sjoukje F Oosting, Bernard F A M van der Laan, Jan L Roodenburg, Hendrik P Bijl, György B Halmos, Boudewijn E C Plaat
OBJECTIVE: Salvage surgery has a higher complication rate compared to primary surgical treatment. We evaluated clinical outcome of salvage neck dissections in relation to initial treatment modality, extent of surgery, and patient related factors. DESIGN: Single institution consecutive case series. SETTING: Tertiary Head and Neck Cancer Center. PARTICIPANTS: Eighty-seven patients with head and neck squamous cell carcinoma, who underwent salvage neck dissection after initial radiotherapy (n=30), radiotherapy with carboplatin/5-fluorouracil (n=43), or radiotherapy with cetuximab (n=14)...
December 29, 2016: Clinical Otolaryngology
https://www.readbyqxmd.com/read/28032719/minichromosome-maintenance-protein-7-and-geminin-expression-prognostic-value-in-laryngeal-squamous-cell-carcinoma-in-patients-treated-with-radiotherapy-and-cetuximab
#4
Giovanni Almadori, Libero Lauriola, Antonella Coli, Francesco Bussu, Roberto Gallus, Domenico Scannone, Vincenzo Valentini, Gaetano Paludetti, Thomas E Carey, Franco O Ranelletti
BACKGROUND: Minichromosome maintenance protein 7 (MCM7) is a downstream of human epidermal growth receptor (HER1) signaling. We examined MCM7, geminin, and HER1 expression in patients with laryngeal squamous cell carcinoma (SCC) treated with radiotherapy and cetuximab. METHODS: MCM7, geminin, and HER1 were evaluated by immunohistochemistry on 61 patients with laryngeal SCC. The follow-up (median, 32.1 months; range, 2-139 months) went from the beginning of therapy to tumor progression-free survival (PFS) and death (overall survival [OS])...
December 29, 2016: Head & Neck
https://www.readbyqxmd.com/read/28006059/the-kras-variant-and-cetuximab-response-in-head-and-neck-squamous-cell-cancer-a-secondary-analysis-of-a-randomized-clinical-trial
#5
Joanne B Weidhaas, Jonathan Harris, Dörthe Schaue, Allen M Chen, Robert Chin, Rita Axelrod, Adel K El-Naggar, Anurag K Singh, Thomas J Galloway, David Raben, Dian Wang, Chance Matthiesen, Vilija N Avizonis, Rafael R Manon, Omar Yumen, Phuc Felix Nguyen-Tan, Andy Trotti, Heath Skinner, Qiang Zhang, Robert L Ferris, David Sidransky, Christine H Chung
Importance: There is a significant need to find biomarkers of response to radiotherapy and cetuximab in locally advanced head and neck squamous cell carcinoma (HNSCC) and biomarkers that predict altered immunity, thereby enabling personalized treatment. Objectives: To examine whether the Kirsten rat sarcoma viral oncogene homolog (KRAS)-variant, a germline mutation in a microRNA-binding site in KRAS, is a predictive biomarker of cetuximab response and altered immunity in the setting of radiotherapy and cisplatin treatment and to evaluate the interaction of the KRAS-variant with p16 status and blood-based transforming growth factor β1 (TGF-β1)...
December 22, 2016: JAMA Oncology
https://www.readbyqxmd.com/read/28006053/cetuximab-and-radiotherapy-in-laryngeal-preservanion
#6
Luca D'Ascanio, Giampietro Ricci, Fabio Piazza
No abstract text is available yet for this article.
December 22, 2016: JAMA Otolaryngology—Head & Neck Surgery
https://www.readbyqxmd.com/read/28006051/cetuximab-and-radiotherapy-in-laryngeal-preservanion-reply
#7
James A Bonner, Steve Chin, Sharon Spencer
No abstract text is available yet for this article.
December 22, 2016: JAMA Otolaryngology—Head & Neck Surgery
https://www.readbyqxmd.com/read/27997054/stereotactic-body-radiotherapy-for-recurrent-head-and-neck-cancer-a-critical-review
#8
REVIEW
Sujith Baliga, Rafi Kabarriti, Nitin Ohri, Hilda Haynes-Lewis, Ravindra Yaparpalvi, Shalom Kalnicki, Madhur K Garg
The management of patients with recurrent head and neck cancers remains a challenging clinical dilemma. Concerns over toxicity with re-irradiation have limited its use in the clinical setting. Stereotactic Body Radiation Therapy (SBRT) has emerged as a highly conformal and precise type of radiotherapy and has the advantage of sparing normal tissue. Although SBRT is an attractive treatment modality, its use in the clinic is limited, given the technically challenging nature of the procedure. In this review, we attempt to provide a comprehensive overview of the role of re-irradiation in patients with recurrent head and neck cancers, with particular attention to the advent of SBRT and its use with systemic therapies such as cetuximab...
December 20, 2016: Head & Neck
https://www.readbyqxmd.com/read/27986347/subgroup-analysis-according-to-human-papillomavirus-status-and-tumor-site-of-a-randomized-phase-ii-trial-comparing-cetuximab-and-cisplatin-combined-with-radiation-therapy-for-locally-advanced-head-and-neck-cancer
#9
Michela Buglione, Marta Maddalo, Renzo Corvò, Luigi Pirtoli, Fabiola Paiar, Luciana Lastrucci, Marco Stefanacci, Liliana Belgioia, Monica Crociani, Stefania Vecchio, Pierluigi Bonomo, Silvia Bertocci, Paolo Borghetti, Nadia Pasinetti, Luca Triggiani, Loredana Costa, Sandro Tonoli, Salvatore Grisanti, Stefano Maria Magrini
PURPOSE: We report a subgroup analysis primarily focused on human papillomavirus (HPV)-related oropharyngeal cancer (OPC) from the Cetuximab Plus Radiotherapy Versus Cisplatin Plus Radiotherapy in Locally Advanced Head and Neck Cancer (CTXMAB+RT; ClinicalTrials.gov identifier NCT01216020) trial comparing radiation therapy with concomitant cisplatin (CDDP) versus concomitant cetuximab (CTX) as first-line treatment of locally advanced head and neck cancer. METHODS AND MATERIALS: The data from all the patients in the CTXMAB+RT trial were reviewed and separately analyzed in 3 groups: p16-positive OPC, p16-negative OPC, and all other cancer sites...
October 20, 2016: International Journal of Radiation Oncology, Biology, Physics
https://www.readbyqxmd.com/read/27984656/the-toxicity-and-efficacy-of-concomitant-chemoradiotherapy-in-patients-aged-70-years-and-older-with-oropharyngeal-carcinoma-in-the-intensity-modulated-radiotherapy-era
#10
Zachary S Zumsteg, Benjamin H Lok, Allen S Ho, Esther Drill, Zhigang Zhang, Nadeem Riaz, Stephen L Shiao, Jennifer Ma, Sean M McBride, C Jillian Tsai, Shrujal S Baxi, Eric J Sherman, Nancy Y Lee
BACKGROUND: Despite controversy surrounding its benefit, the use of concomitant chemoradiotherapy (CCRT) in patients with oropharyngeal squamous cell carcinoma (OPSCC) who are aged > 70 years is increasing. However, to the authors' knowledge, few studies to date have compared the outcomes of different systemic treatments in this population. METHODS: Records from 74 patients aged ≥ 70 years with stage III to stage IVB OPSCC who were undergoing CCRT from 2002 to 2013 at a single institution were reviewed...
December 16, 2016: Cancer
https://www.readbyqxmd.com/read/27974693/induction-chemotherapy-followed-by-concurrent-chemoradiation-and-nimotuzumab-for-locoregionally-advanced-nasopharyngeal-carcinoma-preliminary-results-from-a-phase-ii-clinical-trial
#11
Jian-Feng Huang, Fu-Zheng Zhang, Qin-Zhou Zou, Le-Yuan Zhou, Bo Yang, Jian-Jun Chu, Jia-Hua Yu, Hao-Wen Zhang, Xiao-Peng Yuan, Guo-Mei Tai, Fen-Ju Liu, C-M Charlie Ma
Overexpression of epidermal growth factor receptor can be found in more than 80% of patients with locoregionally advanced nasopharyngeal carcinoma and is associated with shorter survival. In this work, we evaluated the feasibility of adding nimotuzumab to chemoradiation in locoregionally advanced nasopharyngeal carcinoma. Twenty-three patients with clinically staged T3-4 or any node-positive disease were enrolled. They were scheduled to receive one cycle of induction chemotherapy followed by intensity-modulated radiotherapy, weekly administration of nimotuzumab and concurrent chemotherapy...
December 10, 2016: Oncotarget
https://www.readbyqxmd.com/read/27959944/bemer-electromagnetic-field-therapy-reduces-cancer-cell-radioresistance-by-enhanced-ros-formation-and-induced-dna-damage
#12
Katja Storch, Ellen Dickreuter, Anna Artati, Jerzy Adamski, Nils Cordes
Each year more than 450,000 Germans are expected to be diagnosed with cancer subsequently receiving standard multimodal therapies including surgery, chemotherapy and radiotherapy. On top, molecular-targeted agents are increasingly administered. Owing to intrinsic and acquired resistance to these therapeutic approaches, both the better molecular understanding of tumor biology and the consideration of alternative and complementary therapeutic support are warranted and open up broader and novel possibilities for therapy personalization...
2016: PloS One
https://www.readbyqxmd.com/read/27938998/epidermal-growth-factor-receptor-egfr-pathway-polymorphisms-as-predictive-markers-of-cetuximab-toxicity-in-locally-advanced-head-and-neck-squamous-cell-carcinoma-hnscc-in-a-spanish-population
#13
J Fernández-Mateos, R Seijas-Tamayo, R Mesía, M Taberna, M Pastor Borgoñón, E Pérez-Ruiz, J C Adansa Klain, S Vázquez Fernández, E Del Barco Morillo, A Lozano, R González Sarmiento, J J Cruz-Hernández
OBJECTIVES: To examine the relationship between polymorphisms of the epidermal growth factor receptor (EGFR) pathway and toxicity in head and neck squamous cell carcinoma (HNSCC) patients treated with cetuximab. MATERIAL AND METHODS: Multicenter, retrospective, observational pilot study which included 110 patients with histologically-confirmed human papillomavirus (HPV) negative HNSCC in locally advanced stages (III-IVA-B) and who were treated with chemotherapy and radiotherapy plus cetuximab between 2003 and 2013...
December 2016: Oral Oncology
https://www.readbyqxmd.com/read/27895498/meta-analysis-of-outcomes-of-patients-with-stage-iv-colorectal-cancer-managed-with-chemotherapy-radiochemotherapy-with-and-without-primary-tumor-resection
#14
Ko-Chao Lee, Yu-Che Ou, Wan-Hsiang Hu, Chia-Cheng Liu, Hong-Hwa Chen
BACKGROUND: Colorectal cancer is the third leading cause of death worldwide. Currently, novel chemotherapeutic agents are first-line therapy for unresectable stage IV colorectal cancer, while benefits of noncurative primary tumor resection in advanced disease remain debatable. OBJECTIVE: This meta-analysis evaluated outcomes of patients with unresectable stage IV colorectal cancer receiving systemic chemotherapy with or without primary tumor resection. MATERIALS AND METHODS: A database search of PubMed and Cochrane Library databases identified 167 studies that were screened for relevance...
2016: OncoTargets and Therapy
https://www.readbyqxmd.com/read/27880014/inhibition-of-epithelial-mesenchymal-transition-by-cetuximab-via-the-egfr-gep100-arf6-amap1-pathway-in-head-and-neck-cancer
#15
Yoshifumi Matsumoto, Hiroyuki Sakurai, Yasunao Kogashiwa, Toru Kimura, Yuma Matsumoto, Takashi Shionome, Masatake Asano, Koichiro Saito, Naoyuki Kohno
BACKGROUND: Despite improved survival by the addition of a monoclonal antibody against epidermal growth factor receptor (EGFR), cetuximab, to chemotherapy or radiotherapy for squamous cell carcinoma of the head and neck (SCCHN), cetuximab by itself is not a potent antiproliferative agent against SCCHN. We aimed to elucidate working mechanism of cetuximab in SCCHN. METHODS: The effect of cetuximab on the proliferation, migration, invasion, epithelial-mesenchymal transition, and signaling events downstream of the EGFR were investigated in 4 SCCHN cell lines...
November 23, 2016: Head & Neck
https://www.readbyqxmd.com/read/27831000/targeted-therapies-for-the-treatment-of-non-small-cell-lung-cancer-monoclonal-antibodies-and-biological-inhibitors
#16
Ana P S Silva, Priscila V Coelho, Maristella Anazetti, Patricia U Simioni
The usual treatments for patients with non-small-cell lung cancer (NSCLC), such as advanced lung adenocarcinoma, are unspecific and aggressive, and include lung resection, radiotherapy and chemotherapy. Recently, treatment with monoclonal antibodies and biological inhibitors has emerged as an effective alternative, generating effective results with few side effects. In recent years, several clinical trials using monoclonal antibodies presented potential benefits to NSCLC, and four of them are already approved for the treatment of NSCLC, such as cetuximab, bevacizumab, nivolumab and pembrolizumab...
November 10, 2016: Human Vaccines & Immunotherapeutics
https://www.readbyqxmd.com/read/27825651/sequential-four-drug-chemotherapy-and-intensity-modulated-radiotherapy-for-larynx-preservation-in-resectable-advanced-larynx-and-hypopharynx-cancer-a-pilot-study
#17
Xuan Su, Caiyun He, Tao Tang, Weichao Chen, Zhaoqu Li, Yong Chen, Ankui Yang
OBJECTIVE: The value of additional use of cetuximab with the classical cisplatin, docetaxel and 5-fluorouracil regimen in larynx preservation remains unknown. This study was designed to resolve this issue and appraise its toxicity. MATERIALS AND METHODS: Thirteen untreated patients with stage III-IV larynx or hypopharynx squamous cell carcinoma were recruited and received two cycles of C+TPF regimen (cetuximab plus docetaxel, cisplatinand and 5-fluorouracil), followed by one more cycle of C+TPF and intensity-modulated radiotherapy (70Gy)...
January 2017: American Journal of Otolaryngology
https://www.readbyqxmd.com/read/27813277/comparison-between-weekly-cisplatin-enhanced-radiotherapy-and-cetuximab-enhanced-radiotherapy-in-locally-advanced-head-and-neck-cancer-first-retrospective-study-in-asian-population
#18
Sheh Rawat, Parveen Ahlawat, Anjali Kakria, Gaurav Kumar, Ranga Rao Rangaraju, Abhishek Puri, Manoj Pal, Deepika Chauhan, Bharti Devnani, Pranav Chadha
AIM: To present a direct comparison between chemotherapy-enhanced radiotherapy (CERT) and biotherapy-enhanced radiotherapy (BERT) in locally advanced head and neck cancer. METHODS: It is a retrospective analysis of 53 patients with locally advanced head and neck cancer treated from August 2006 to December 2008. For CERT, patients received weekly cisplatin (40 mg/m(2) ) and for BERT, a loading dose of 400 mg/m(2) of cetuximab given one week prior to radiotherapy followed by 250 mg/m(2) given weekly along with radiotherapy...
November 3, 2016: Asia-Pacific Journal of Clinical Oncology
https://www.readbyqxmd.com/read/27757500/-association-of-hpv-infection-p16%C3%A2-status-and-efficacy-of-radiotherapy-with-or-without-cetuximab-in-advanced-oropharyngeal-squamous-cell-carcinoma
#19
Carsten Nieder
No abstract text is available yet for this article.
October 18, 2016: Strahlentherapie und Onkologie: Organ der Deutschen Röntgengesellschaft ... [et Al]
https://www.readbyqxmd.com/read/27741378/assessing-feasibility-compliance-and-toxicity-of-concomitant-chemo-radiotherapy-in-head-and-neck-cancers-in-the-northern-territory-initial-experience-and-challenges
#20
Ajay Gupta, Siddhartha Baxi, Christopher Hoyne
INTRODUCTION: Comprehensive oncology services have recently been introduced in the Northern Territory (NT) enabling delivery of concurrent chemo-radiotherapy (CCRT) in locally advanced head and neck squamous cell carcinoma (LAHNSC). The purpose of this study is to assess feasibility, compliance and toxicity of CCRT in remote Australia. METHODS: Chart review was conducted for all patients >18 years, with biopsy-proven LAHNSC, receiving curative intent CCRT between January 2010 and September 2012...
July 1, 2016: Journal of Medical Radiation Sciences
keyword
keyword
104263
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"